Literature DB >> 33982900

Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank.

Lauren Prisco1, Matthew Moll2, Jiaqi Wang1, Brian D Hobbs2, Weixing Huang1, Lily W Martin1, Vanessa L Kronzer3, Sicong Huang2, Edwin K Silverman2, Tracy J Doyle2, Michael H Cho2, Jeffrey A Sparks2.   

Abstract

OBJECTIVE: To investigate the independent relationship of rheumatoid arthritis (RA) to the type and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in general population controls.
METHODS: In this cross-sectional study, we investigated the association of RA with pulmonary function measures on spirometry among subjects in the UK Biobank who underwent spirometry for research purposes. RA cases were identified based on self-report and current disease-modifying antirheumatic drug/glucocorticoid use. Controls were subjects without RA from the general population. Outcome measures included continuous forced expiratory volume in 1 second percent predicted (FEV1 %) and forced vital capacity percent predicted (FVC%), type of spirometric pattern (restrictive or obstructive), and severity of the restrictive or obstructive pattern. We used multivariable regression to estimate the effects in RA cases compared to the effects in controls, adjusting for age, sex, body mass index, and smoking status/pack-years.
RESULTS: Among 350,776 analyzed subjects who underwent spirometry (mean age 56.3 years; 55.8% female; 45.5% ever smokers), we identified 2,008 cases of treated RA. In multivariable analyses, RA was associated with lower FEV1 % (β = -2.93 [95% confidence interval (95% CI) -3.63, -2.24]), FVC% (β = -2.08 [95% CI -2.72, -1.45]), and FEV1 /FVC (β = -0.008 [95% CI -0.010, -0.005]) compared to controls. RA was additionally associated with restrictive patterns (odds ratio [OR] 1.36 [95% CI 1.21, 1.52]) and obstructive patterns (OR 1.21 [95% CI 1.07, 1.37]) independent of confounders, and was most strongly associated with severe restrictive and obstructive patterns.
CONCLUSION: RA is associated with increased odds of restrictive and obstructive patterns, and this relationship is not explained by confounders, including smoking status. In addition to restrictive lung disease, clinicians should also be aware that airway obstruction may be a pulmonary manifestation of RA.
© 2021, American College of Rheumatology.

Entities:  

Mesh:

Year:  2021        PMID: 33982900      PMCID: PMC8568623          DOI: 10.1002/art.41791

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  47 in total

1.  Interpreting COPD prevalence estimates: what is the true burden of disease?

Authors:  R J Halbert; Sharon Isonaka; Dorothy George; Ahmar Iqbal
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

2.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

3.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

4.  A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality.

Authors:  Charlotte Hyldgaard; Ole Hilberg; Alma Becic Pedersen; Sinna Pilgaard Ulrichsen; Anders Løkke; Elisabeth Bendstrup; Torkell Ellingsen
Journal:  Ann Rheum Dis       Date:  2017-06-13       Impact factor: 19.103

Review 5.  Obstructive lung diseases and risk of rheumatoid arthritis.

Authors:  H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks
Journal:  Expert Rev Clin Immunol       Date:  2020-01-06       Impact factor: 4.473

6.  Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.

Authors:  Karina Raimundo; Joshua J Solomon; Amy L Olson; Amanda M Kong; Ashley L Cole; Aryeh Fischer; Jeffrey J Swigris
Journal:  J Rheumatol       Date:  2018-11-15       Impact factor: 4.666

7.  Obstructive pulmonary disease in rheumatoid arthritis.

Authors:  R L Collins; R A Turner; A M Johnson; N O Whitley; R L McLean
Journal:  Arthritis Rheum       Date:  1976 May-Jun

8.  Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second.

Authors:  G M Patterson; S Wilson; J L Whang; J Harvey; K Agacki; H Patel; J Theodore
Journal:  J Heart Lung Transplant       Date:  1996-02       Impact factor: 10.247

Review 9.  The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis.

Authors:  Jeffrey A Sparks; Elizabeth W Karlson
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

10.  Respiratory Diseases as Risk Factors for Seropositive and Seronegative Rheumatoid Arthritis and in Relation to Smoking.

Authors:  Vanessa L Kronzer; Helga Westerlind; Lars Alfredsson; Cynthia S Crowson; Fredrik Nyberg; Göran Tornling; Lars Klareskog; Marie Holmqvist; Johan Askling
Journal:  Arthritis Rheumatol       Date:  2020-12-04       Impact factor: 10.995

View more
  1 in total

1.  Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)-associated Bronchiectasis: Role of RA-related Autoantibodies.

Authors:  Gregory McDermott; Ritu Gill; Staci Gagne; Suzanne Byrne; Weixing Huang; Xiaosong Wang; Lauren C Prisco; Alessandra Zaccardelli; Lily W Martin; Lucy Masto; Vanessa L Kronzer; Nancy Shadick; Paul F Dellaripa; Tracy J Doyle; Jeffrey A Sparks
Journal:  J Rheumatol       Date:  2022-03-15       Impact factor: 5.346

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.